Evidence map›Paper›PMID 39852571›Full record

ReviewJournal of functional biomaterials2025

From Blood to Therapy: The Revolutionary Application of Platelets in Cancer-Targeted Drug Delivery.

Lijuan Xie, Fengxu Gan, Yun Hu, Yibin Zheng, Junshan Lan, Yuting Liu, Xiaofang Zhou, Jianyu Zheng, Xing Zhou, Jie Lou

Abstract readReview
In one paragraph

Review in Journal of functional biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lijuan XieSchool of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing 400054, China.
Fengxu GanSchool of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing 400054, China.
Yun HuSchool of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing 400054, China.
Yibin ZhengSchool of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing 400054, China.
Junshan LanSchool of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing 400054, China.
Yuting LiuSchool of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing 400054, China.
Xiaofang ZhouSchool of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing 400054, China.
Jianyu ZhengSchool of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing 400054, China.
Xing ZhouYunnan Key Laboratory of Stem Cell and Regenerative Medicine, School of Rehabilitation, Kunming Medical University, Kunming 650500, China.ORCID 0000-0003-0852-0687
Jie LouSchool of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing 400054, China.ORCID 0000-0001-6639-9913

Funding

Action plan for high-quality Development of graduate education of Chongqing University of Technology gzlcx20233380Chongqing University of Technology National Fund Cultivation Project 2022PYZ038
6 · The paper itself

Abstract

Biomimetic nanodrug delivery systems based on cell membranes have emerged as a promising approach for targeted cancer therapy due to their biocompatibility and low immunogenicity. Among them, platelet-mediated systems are particularly noteworthy for their innate tumor-homing and cancer cell interaction capabilities. These systems utilize nanoparticles shielded and directed by platelet membrane coatings for efficient drug delivery. This review highlights the role of platelets in cancer therapy, summarizes the advancements in platelet-based drug delivery systems, and discusses their integration with other cancer treatments. Additionally, it addresses the limitations and challenges of platelet-mediated drug delivery, offering insights into future developments in this innovative field.

Indexed as

bionic nanosystemscancercell membraneplatelettargeted therapy

Identifiers

PMID39852571
PMCPMC11766108

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.